Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.

Investment Management

Lilly Asia Ventures

Lilly Asia Ventures' headquarters in Hong Kong

Managing Directors

Jieyu Zou

Stella Shi

Yvonne Wu

Yuan Chen

Sean Zhang

Ting Feng

Tao Yu

Lilian Wan

Hansen Xu

Xiaodi Su

Liang Lin

Josh Jin

Lilly Asia Ventures' Leadership Team includes Liang Lin and 26 others.

Leadership Team

Lilly Asia Ventures

Org chart

Teams

Leadership Team

Offices

Lilly Asia Ventures

Org chart

Teams

Leadership Team

Offices

Related companies